Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cerebral Hemorrhage Clear all
Completed Phase 1Phase 2 Interventional Results available

Argatroban Stroke Treatment - A Pilot Safety Study

NCT00268762
View directory record Official record
Conditions
Ischemic Stroke
Interventions
argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 11, 2026, 2:59 PM EDT
Recruiting Not applicable Interventional

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

NCT06347796
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Conventional Surgery, Middle Meningeal Artery Embolization (MMAE)
Procedure · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 11, 2026, 2:59 PM EDT
Terminated Phase 3 Interventional Results available

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

NCT00585559
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 11, 2026, 2:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Not applicable Interventional

DCS Study in Extremely Premature Newborns

NCT04367181
View directory record Official record
Conditions
Premature Birth, Extremely Low Birth Weight, Infant, Small for Gestational Age, Intracerebral Hemorrhage
Interventions
Diffuse Correlation Spectroscopy (DCS), Amplitude Integrated Electroencephalography (aEEG)
Device
Lead sponsor
Maria Angela Franceschini
Other
Eligibility
0 Hours to 72 Hours
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 11, 2026, 2:59 PM EDT
Active, not recruiting Phase 2 Interventional

The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition

NCT03068442
View directory record Official record
Conditions
Cognitive Impairment, Carotid Artery Plaque, Inflammation
Interventions
Imaging with flutemetamol F 18 PET/CT
Drug
Lead sponsor
Scott Mcnally
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

PRET: Patients Prone to Recurrence After Endovascular Treatment

NCT00626912
View directory record Official record
Conditions
Intracranial Aneurysm, Subarachnoid Hemorrhage
Interventions
endovascular coil embolization
Procedure
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Gainesville, Florida • Kalamazoo, Michigan • Rochester, Minnesota + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm

NCT03377049
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Vasospasm, Cerebral
Interventions
Acetazolamide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 11, 2026, 2:59 PM EDT
Recruiting Phase 3 Interventional

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Recombinant Factor VIIa, Biological/Vaccine: Placebo
Biological
Lead sponsor
Joseph Broderick, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

NCT00593268
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Terminated Not applicable Interventional

Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage

NCT00665769
View directory record Official record
Conditions
Intraventricular Hemorrhage, Autoregulation
Interventions
Hypercapnia, Normocapnia
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 7 Days
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Not applicable Interventional Results available

INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage

NCT02661672
View directory record Official record
Conditions
Intracranial Hemorrhage
Interventions
Apollo Device, Artemis Device
Device
Lead sponsor
J. Mocco
Other
Eligibility
22 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Louisville, Kentucky • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

NCT03691727
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
David Hasan
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 11, 2026, 2:59 PM EDT
Enrolling by invitation Phase 4 Interventional

CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance

NCT07643493
View directory record Official record
Conditions
Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
Interventions
Tissue Plasminogen Activator (tPA), Isotonic solution
Drug · Procedure
Lead sponsor
David Dornbos
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436
View directory record Official record
Conditions
Traumatic Brain Injury, Subarachnoid Hemorrhage
Interventions
Levetiracetam, Phenytoin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

NCT00666328
View directory record Official record
Conditions
Hypertension, Hemorrhage
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 11, 2026, 2:59 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet

NCT03495206
View directory record Official record
Conditions
Stroke, Acute, Intracranial Hemorrhages
Interventions
Y-2(Edaravone And Borneol) Sublingual Tablet
Drug
Lead sponsor
Yantai YenePharma Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 11, 2026, 2:59 PM EDT
Recruiting No phase listed Observational

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326
View directory record Official record
Conditions
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Interventions
Not listed
Lead sponsor
Peter Merkel
Other
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Recruiting Phase 2Phase 3 Interventional

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

NCT06621329
View directory record Official record
Conditions
SAH (Subarachnoid Hemorrhage), Headache
Interventions
Transnasal sphenopalatine ganglion block
Combination Product
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Recruiting Phase 4 Interventional

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

NCT06119061
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
Telavancin Injection
Drug
Lead sponsor
Aaron Cook
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 11, 2026, 2:59 PM EDT
Completed Not applicable Interventional Results available

HEAL-LAA Clinical Trial

NCT05809596
View directory record Official record
Conditions
Atrial Fibrillation, Bleeding, Stroke
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 11, 2026, 2:59 PM EDT
Completed No phase listed Observational

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

NCT01158807
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Not listed
Lead sponsor
Unity Health Toronto
Other
Eligibility
Not listed
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 11, 2026, 2:59 PM EDT
Withdrawn Not applicable Interventional

Stereotactic, Robot-assisted Intracerebral Hemorrhage Clot Evacuation

NCT03414307
View directory record Official record
Conditions
Intracerebral Hematoma
Interventions
Intracerebral catheter placement, Robot-assisted intracerebral catheter
Procedure · Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 11, 2026, 2:59 PM EDT